Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
  • B01D67/0002—Organic membrane manufacture
  • B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
  • B01D67/0013—Casting processes
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
  • B01D67/0002—Organic membrane manufacture
  • B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
  • B01D67/0016—Coagulation
  • B01D67/00165—Composition of the coagulation baths
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
  • B01D69/12—Composite membranes; Ultra-thin membranes
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D2323/00—Details relating to membrane preparation
  • B01D2323/219—Specific solvent system
  • B01D2323/22—Specific non-solvents or non-solvent system
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D2323/00—Details relating to membrane preparation
  • B01D2323/42—Details of membrane preparation apparatus
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D2325/00—Details relating to properties of membranes
  • B01D2325/02—Details relating to pores or porosity of the membranes
  • B01D2325/022—Asymmetric membranes
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/249921—Web or sheet containing structurally defined element or component
  • Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
  • Y10T428/249978—Voids specified as micro
  • Y10T428/24998—Composite has more than two layers

Definitions

• the present invention relates to a method for forming microporous membranes.
• Microporous membranes with diverse properties are used in many modern products, including such things as filters, breathable articles, absorbent articles, and medical articles.
• microporous membranes, 10 including inducing a phase inversion in a dope layer. By manipulating the conditions that trigger the phase inversion, different morphologies can be generated in the resulting microporous membrane, adapting it to the specific needs of the end user.
• microporous membranes are further 15 described in U.S. Patent Nos. 6,736,971 (Sale et al.); 5,869,174 (Wang); 6,632,850
• Microporous membranes having a microstructure are described.
• the present disclosure describes a method for forming microporous membrane sheets.
• the microporous membrane is formed from a dope formulation and a first coagulant formulation.
• the dope formulation comprises a polymeric material and a solvent.
• the 0 first coagulant formulation comprises a coagulant and a coating adjuvant.
• the dope and first coagulant formulations are simultaneously cast through a multilayer extrusion die.
• the dope formulation layer is cast on to the coagulant formulation forming an interface.
• a first surface of the dope formulation layer is located opposite the interface. At the interface, a portion of the first coagulant formulation layer diffuses into the dope formulation layer effecting a first phase inversion.
• the first phase inversion results from the first coagulant of the first coagulant formulation contacting the polymeric material of the dope formulation reducing the thermodynamic stability of the polymeric material in the solvent.
• the first phase inversion forms a first microstructure of a microporous membrane.
• a first surface of a microporous membrane is contacted with a second coagulant, where the second coagulant is a vapor.
• a portion of the second coagulant diffuses through the first surface of the dope formulation layer effecting a second phase inversion.
• the second phase inversion forms a second microstructure of the microporous membrane.
• a method for forming a microporous membrane sheet having at least two microstructures is described.
• the microporous membrane is formed from a dope formulation simultaneously cast with first and second coagulant formulations.
• the second coagulant formulation comprises a third coagulant and a second coating adjuvant.
• the dope formulation may be simultaneously cast between the first and second coagulant formulations with a multilayer extrusion die.
• a first interface is formed between the dope formulation and the first coagulant formulation, and a second interface is formed between the dope formulation and the second coagulant formulation. The first interface is opposite the second interface.
• a portion of the first coagulant formulation diffuses into the dope formulation through the first interface effecting a first phase inversion, and a portion of the second coagulant formulation diffuses into the dope formulation through the second interface effecting a second phase inversion.
• the first and second phase inversions form first and second microstructures of a microporous membrane, respectively.
• the first and second microstructures may be different or the same.
• a second coagulant formulation comprising a third coagulant and a second coating adjuvant is cast sequentially on the first surface of the dope formulation layer after simultaneously casting dope and first coagulant formulations.
• Microporous membranes are commonly formed having dope layers exposed to a coagulation bath causing a phase inversion.
• dope and coagulant formulations and/or coagulants contact one another as layers to effect a phase inversion resulting in forming microstructures.
• Casting the formulations simultaneously with a multilayer extrusion die forming a multilayer sheet removes the step of subjecting the dope layers to coagulation baths.
• a multilayer extrusion die removes the cost and complexities of multiple step coating processes, where individual layers are coated.
• a multilayer extrusion die allows for coating of multiple thin layers which may be difficult with wet on wet coating methods.
• a multilayer sheet having thin layers may be formed having layers of specific thicknesses to meet particular specifications as a multilayer membrane.
• a coagulant formulation having a coating adjuvant of this disclosure provides for selecting a rate of phase inversion, controlling the depth of the phase inversion within the thickness of the membrane, and selecting a microstructure for the membrane.
• FIG. 1 is a schematic representation of a multilayer extrusion die.
• FIG. 2 is a schematic representation of an expanded view of detail 2 taken in FIG.
• FIG. 3 is a schematic representation of multilayer sheet having a dope formulation layer on a coagulant formulation layer.
• FIG. 4 is a schematic representation of a multilayer sheet having a dope layer in between a first and second coagulant formulation layers.
• FIG. 5 is a SEM micrograph of a microporous membrane having a microstructure of Example 1.
• FIG. 6 is a SEM micrograph cross-section of a microporous membrane having first and second microstructures of Example 2.
• FIG. 7 is a SEM micrograph (planar view) of a microporous membrane of FIG. 6.
• FIG. 8 is a SEM micrograph cross-section of a microporous membrane having first and second microstructures of Example 3.
• the term "dope formulation” refers to a polymeric material dissolved in a solvent at a selected concentration for forming a thermodynamically stable dope formulation.
• the solvent is referred to as a "good” or compatible solvent for the polymeric material.
• the dope formulation has a suitable viscosity for simultaneously casting with at least one coagulant formulation.
• the dope formulation may optionally further comprise a porogen
• the term "coagulant formulation” refers to a coagulant and a coating adjuvant useful in a liquid-polymer induced phase separation.
• the coagulant (that is, liquid) can be a "nonsolvent” for the polymeric material of the dope formulation.
• the coagulant may be generally regarded as incompatible with the polymeric material.
• the coagulant reduces the thermodynamic stability of the polymeric material in a solvent of the dope formulation.
• the coagulant formulation has a suitable viscosity for simultaneously casting with a dope formulation.
• the coagulant formulation may optionally further comprise more than one coating adjuvant, and/or more than one coagulant.
• coating adjuvant refers to an additive(s) dissolved or dispersed in a coagulant formulation.
• the coating adjuvant(s) can be added to adjust the viscosity of the coagulant formulation sufficient for casting on to a dope formulation.
• concentration of the coating adjuvant(s) may be selected to control the rate of phase inversion, to control the depth of the phase inversion, or to form a specific microstructure of the membrane.
• the term "simultaneously casting” refers to forming at least two or more layers on to each other to form a multilayered sheet.
• the dope and coagulant formulation layers may be cast through a multilayer extrusion die, where the formulation layers immediately contact each other at the exit of the die.
• the die may be used to meter the dope formulation and coagulant formulations having sufficient viscosity, such that the thickness of the layers is substantially controlled through the control of the formulation feed rate.
• phase inversion refers to the transformation of a homogenous system (for example, dope formulation) into two or more phases.
• a homogeneous polymer solution can be precipitated into two phases: a solid polymer-rich phase, and a liquid polymer-poor phase.
• phase inversion results from a process of exposing a dope formulation to a coagulant formulation, where each of the formulations have sufficient viscosity to be simultaneously cast as layers through, for example, a multilayer extrusion die so as to form sheets.
• phase inversion mechanisms include thermal induced phase inversion and liquid-liquid phase inversion.
• microstructure refers to a porous structure.
• the porous structure may comprise openings which may be assymetrical or symmetrical.
• a membrane may have more than one porous structure.
• the porous structure may result from a phase inversion of polymeric material, where polymer-rich regions may form the structure, and the polymer-poor regions may form the openings within the structure.
• the porous structures may be different or the same.
• the pores of a porous structure may have an average diameter of 0.05 to 25 microns.
• the recitation of numerical ranges by endpoints includes all numbers subsumed within that range (for example, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.8, 4, and 5).
• a dope formulation may be cast as a layer for forming a sheet.
• the dope formulation comprises a polymeric material which can dissolve in a solvent with optional additives (for example, porogens) and/or nonsolvents to form a substantially homogeneous stable formulation.
• the dope formulation may be thermodynamically stable at room temperature without visible phase separation.
• Dope formulations may be formed from one or more formulations having suitable concentrations of solvents and/or nonsolvents.
• concentration of the dope formulation can be changed to accommodate a particular microstructure, and also to maintain the integrity of the membrane. If a concentration of a polymer material in a dope formulation is too low, a membrane may not be formed. If the concentration is too high, an undesired irregular microstructure may result.
• the concentration of the polymeric material in the dope formulation may vary based on the solvents, additives and nonsolvents used for constructing the membrane.
• the concentration or percent solids of a polymeric material dissolved in a solvent of a dope formulation may be selected to achieve a viscosity and/or surface tension sufficient for casting as a layer in a multilayer sheet.
• the concentration is selected to be sufficient to allow diffusion of a coagulant formulation through an interface of the coextruded layers.
• the concentration of the polymeric material in a solvent of the dope formulation may be in a range of 10 to 25 weight percent.
• the concentration of the polymeric material is in a range of 10 to 20 weight percent.
• the viscosity of a dope formulation may be selected for casting as a dope formulation layer on a coagulant formulation layer in a multilayer sheet.
• the viscosity is selected to provide stable layer formation at a line speed of, for example, a moving substrate.
• surface tension, general bead stability and other fluid properties of the formulations may be selected to ensure coating uniformity.
• the stable layer formation promotes predictable diffusion of a portion of the coagulant formulation at the first surface of the dope and coagulant formulation layers.
• An appropriate choice for the viscosity of the dope formulation also promotes the development of a uniform thickness of the dope formulation layer, and ultimately a uniform thickness of the microporous sheet that will be formed.
• the viscosity of the dope formulation may be in a range of 20 to 4,000 centipoise.
• the viscosity of the dope formulation is in a range of 25 to 2,000 centipoise, and more preferably, in a range of 25 to 1,000 centipoise.
• polymeric materials are available and can be used for the formation of membranes of this disclosure.
• the polymeric materials or a blend of polymeric materials may be used for a dope formulation.
• polymeric materials may include polyethersulfones, polyetherimides, polyimides, polyamides, polysulfones, polyarylsulphones, polyvinyl chloride, polyethylene terephthalate, polycarbonates, polyolefms such as polyethylene or polypropylene, cellulose esters such as cellulose acetate or cellulose nitrate, polystyrenes, acrylic polymers, methacrylic polymers, copolymers of acrylic or methacrylic polymers, and combinations thereof.
• the dope formulation can be a solution of the solvent and of polymers that can be amorphous, crystalline, noncrystalline or partially crystalline.
• the polymeric material of the dope formulation is polyetherimide (I).
• the polymeric material of the dope formulation is polyethersulfone (II).
• the solvent of a dope formulation dissolves the polymeric material to provide a homogeneous solution.
• the solvent of the dope solution can be a solvent for an optional nonsolvent, that is, for the polymeric material, and optional additives present in the dope formulation.
• the nonsolvent may be added to the formulation at a concentration in a range of 0.05 to 5 weight percent. Selection of a solvent for the membrane may influence properties, such as the rate of phase inversion or the type of microstructure, when the dope formulation contacts a coagulant formulation.
• solvents for the dope formulation may include water, dimethyl formamide, N, N-dimethylacetamide, N-methyl-2- pyrrolidinone, tetramethylurea, acetone, methyl ethyl ketone, methyl acetate, ethylacetate and other alkyl acetates, dimethylsulfoxide and combinations thereof.
• the solvent may be oligomeric or polymeric in nature forming a polymer blend with the polymeric material.
• the solvent of the dope formulation may comprise more than one solvent, a blend of solvents, or a nonsolvent for phase inversion.
• a nonsolvent is a material that is miscible in the solvent of the dope formulation, but which, by itself, is insoluble with the polymer or may cause coagulation of the polymer.
• the nonsolvent may be added to a solvent to influence the rate of a phase inversion or aid in the development of a microstructure.
• polymer solvents may be categorized as good solvents, nonsolvents, and poor solvents.
• Good solvents are those in which the interactions (forces) between the polymer molecules and solvent molecules are greater than the forces of attraction between one polymer molecule and another polymer molecule. The reverse is true for nonsolvents.
• Poor solvents are those in which the interactions between the polymer and solvent are equal to the forces of attraction between one polymer and another polymer molecule.
• a stable homogeneous dope formulation can be obtained by first dissolving a polymer in a good solvent (for example, when polyethersulfone is the polymer, the use of N-methyl-2- pyrrolidinone as the solvent).
• a good solvent for example, when polyethersulfone is the polymer, the use of N-methyl-2- pyrrolidinone as the solvent.
• good solvents for polyethersulfone include dimethylacetamide, dioxane, dimethylsulfoxide, chloroform, tetramethylurea, and tetrachloroethane.
• Hildebrand solubility parameters refer to a solubility parameter represented by the square root of the cohesive energy density of a material, having units of (pressure) 1 2 , and being equal to ( ⁇ H-RT) 1 2 V 1 2 where ⁇ H is the molar vaporization enthalpy of the material, R is the universal gas constant, T is the absolute temperature, and V is the molar volume of the solvent.
• Hildebrand solubility parameters are tabulated for solvents in: Barton, A. F. M., "Handbook of Solubility and Other Cohesion Parameters", 2 nd Ed., CRC Press, Boca Raton, FIa.
• a coagulant formulation may be cast as a layer of a multilayer sheet for forming microporous membranes.
• the coagulant formulation can comprise a coagulant and a coating adjuvant. In some embodiments, the coagulant does not comprise a coating adjuvant.
• the coagulant can be a nonsolvent for the polymeric material of the dope formulation.
• Membranes may be formed from a coagulant formulation simultaneously cast with a dope formulation resulting in a phase inversion and the formation of a microstructure.
• the coagulant of the coagulant formulation has a concentration selected to reduce the thermodynamic stability of the dope formulation when the formulations are cast as layers.
• the coagulant is considered a nonsolvent for the polymeric material of the dope formulation, where the polymeric material is insoluble in the coagulant.
• the attraction between the coagulant molecules and the polymer chains of the polymeric material is less than the attraction between one polymer chain of the material and a second polymer chain of the same polymeric material.
• the coagulant may have limited solubility in the solvent of the dope formulation.
• the solvent of the dope formulation is preferred to be miscible with the coagulant during membrane formation.
• Examples of coagulants of a coagulant formulation may include water, alcohols, ethers, oligoalkyleneoxides and ethers of oligoalkyleneoxides, polyalkyleneoxides and their ethers.
• R 1 and R 3 may be the same or different.
• coagulants as nonsolvents for a polymeric material (for example, polyethersulfone) of a dope formulation may include 2-methoxyethanol, propionic acid, t-amyl alcohol, methanol, ethanol, isopropanol, hexanol, heptanol, octanol, acetone, methyethyl ketone, methylisobutylketone, butyl ether, ethyl acetate amyl acetate, glycerol, diethyleneglycol dibutylether, and water.
• the concentration of coagulant may be determined by the polymeric material and the solvent of the dope formulation, and by the processing conditions for preparation of a membrane.
• a coagulant of a coagulant formulation for polyethersulfone is water.
• a coagulant formulation can have a viscosity sufficient to allow diffusion of a portion of the coagulant formulation through a first surface formed with a dope formulation layer.
• the viscosity of the coagulant formulation may be adjusted by the addition of a coating adjuvant to provide a uniform thickness as a coagulant formulation layer when cast on to the dope formulation layer.
• Other coating formulation properties to be considered include surface tension, general bead stability and other formulation properties may be selected to influence coating uniformity of the layers. Materials other than coating adjuvants, such as surfactants, may be added to influence surface tension, interfacial stability, wettability, and dimensional stability.
• the viscosity of the coagulant formulation having a coating adjuvant may be in a range of 20 to 4,000 centipoise.
• the viscosity of the coagulant formulation is in a range of 25 to 2,000 centipoise, and more preferably, in a range of 25 to 1,000 centipoise.
• coating adjuvants include poly(ethylene glycols), polyhydric compounds, polyethers and combinations thereof.
• the concentration of the coating adjuvant of a coagulant formulation is in a range 20 to 95 weight percent.
• the concentration of the coating adjuvant is in a range of 25 to 90 weight percent.
• the coating adjuvant for a coagulant formulation is poly(ethylene glycol).
• the coating adjuvant may be compatible with the polymeric material and/or solvent of the dope formulation layer.
• the coating adjuvant may be added to a coagulant formulation to adjust the viscosity of the coagulant for casting as a layer.
• the coating adjuvant of the coagulant formulation may be added at a concentration sufficient to allow diffusion of a portion of the coagulant formulation through a surface of the cast dope and coagulant formulation layers.
• the coagulant formulation comprises water and poly(ethylene glycol).
• the coagulant may form a homogeneous solution with a coating adjuvant.
• the coagulant formulation may diffuse into the dope formulation layer, and coagulate the polymeric material causing a phase inversion, thus changing the thermodynamic stability of the polymeric material in the solvent of the dope formulation.
• Polymer rich and polymer poor regions may form during the thermodynamic change of the polymeric material in the solvent.
• the polymer rich regions form a continuous structure and the polymer material poor regions form pores of the resulting microstructure.
• the coating adjuvant may be added to a coagulant formulation at a selected concentration to control the rate (kinetics) of the phase inversion forming a membrane.
• the kinetics of the phase inversion may be generally dictated by the process conditions and the components of dope and coagulant formulations.
• the coating adjuvant may be added to a coagulant formulation at a selected concentration for effecting a phase inversion upon contacting the dope formulation layer at a predetermined depth of a thickness of a membrane.
• the thickness of the membrane extends in the z-dimension.
• the depth of the phase inversion may be dictated by the processing conditions and the type of dope and coagulant formulations.
• the depth of the phase inversion resulting in a microstructure may be in a range of 5 to 100 percent of the thickness of the membrane. More preferably, the depth of the phase inversion may be in a range of 5 to 75 percent, and most preferably in a range of 10 to 60 percent.
• a concentration of a coating adjuvant of a coagulant formulation is selected to effect a phase inversion resulting in a defined microstructure upon contacting the dope formulation layer.
• Suitable selection of coagulant formulation and dope formulation layers may yield certain pore size distributions and porosities.
• a membrane formed from the phase inversion of a polyethersulfone dope formulation contacted by two different coagulant formulations on opposite sides may result in a first microstructure having an open celled spongy microstructure on a first surface of, and a second microstructure having interconnected parallel elongated pores extending in a z-dimension on a second surface.
• Multiple microstructures within a membrane referred to as multizone membranes, can provide high throughput and high flux in filtration applications.
• a porogen may be an additive of a dope formulation.
• the porogen may be added to provide for a selected microstructure within the membrane, or to control the rate of phase inversion within the membrane.
• Some examples of porogens include poly(ethylene glycols), polyhydric compounds, polyethers and combinations thereof.
• Tailoring of concentrations of solvents, nonsolvents, polymeric materials, and additives in the dope and coagulant formulations may be used to control the rate of phase inversion, to control the depth of the phase inversion of a multilayered sheet, or to target a specific microstructure for a membrane.
• Metering the flow rate of dope and coagulant formulations may control the depth of a phase inversion in a dope formulation layer(s). Selection of a specific surface of the dope formulation layer to cast the coagulant formulation can be determined prior to depositing the dope and coagulant formulations as a multilayered sheet on a backup roll or temporary support. In other processes described in the art, a coagulation bath used for coagulating the dope layer would have to be continually filtered or the contents of the bath removed and refilled with new coagulants in light of a continuous solvent exchange process.
• the concentration of the polymeric material of the dope formulation and the concentration of the coating adjuvant of the coagulant formulation may be selected to provide suitable formulation viscosities for casting the formulations without or with a backup roll or temporary support.
• the concentration or solids levels of the dope and coagulation formulations may be selected to maintain a viscosity sufficient for casting the dope and coagulant formulations, followed by subsequent phase inversion at an interface between the layers. Viscosities higher than an appropriate range needed for simultaneously casting and phase inversion may form a membrane having little porosity, and where the amount of solids is too low resulting in a low viscosity formulation, a membrane structure may be unattainable.
• FIG. 1 Illustrated in FIG. 1 is a schematic cross-section representation of a multilayer extrusion die 200 which is capable of forming multilayer sheets.
• the multilayer extrusion die 200 includes an extrusion head 220 disposed adjacent to a backup roll 240.
• the backup roll 240 is a rotatable roll that receives extruded layers from the extrusion head 220.
• the backup roll 240 may optionally support a liner 260 to support the coextruded layers (that is, sheet) as they proceed to form a microporous membrane.
• the extrusion head 220 of FIG. 1 includes a dope formulation cavity 320 and coagulant formulation cavities 300, 340 ending in extrusion slots that serve as pathways for coextruding the dope and coagulant formulations.
• the dimensions of the extrusion slots may be conveniently established by placing precision metal shims of a necessary thickness between bars of the die.
• a dope formulation is introduced into cavity 320 so as to subsequently form a dope formulation layer.
• a coagulant formulation may be introduced into cavities 300 and/or 340 to subsequently form coagulant formulation layers on one or more surfaces of the dope formulation layer.
• FIG. 2 an enlarged view of detail 2 taken in FIG. 1 is illustrated.
• the dope and/or coagulant formulation(s) are extruded from extrusion head 220 of FIG. 1, specifically from the extrusion slots extending from cavities 300, 320, 340 creating dope 321 and first 301 and second coagulation 341 formulations.
• the dope 321 and first 301 and second 341 coagulant formulations are drawn away by contact with the rotating backup roll 240.
• the multilayer extrusion die 200 controls the form of the article shaping a cylindrical pipe flow into a sheet.
• Metering of the formulations can be either self-metered, for example, a constant pressure solution handling system feeding a slot die with either pressure pots, head boxes or centrifugal pumps; or pre-metered, for example, a positive displacement syringe pump that meters the flow of formulations to the die cavity relative to the width and speed of the cast multilayer sheet, thereby stabilizing the basis weight of the incompressible liquid sheet at a desired predetermined value.
• a method for forming a two layer sheet 5 comprises simultaneously casting a dope formulation and a coagulant formulation as layers illustrated in FIG. 3. An interface 20 is formed where dope 30 and coagulant 40 formulation layers contact one another.
• a first surface 10 of the dope formulation is located opposite of the interface 20 formed between the cast dope 30 and coagulation 40 formulation layers of the two layer sheet 5. Casting of the dope and coagulant formulations simultaneously further provides for a portion of the coagulant formulation to diffuse into the dope formulation through the interface 20 effecting a phase inversion. The phase inversion of the polymeric material of the dope formulation results in a first microstructure.
• the layer thicknesses depend not only on the multilayer extrusion die geometry, but also on flow and viscosity of the dope and coagulant formulations. Subsequent phase inversion at the first surface 10 of the two layer sheet 5 may occur from the introduction of a vapor as a coagulant.
• Vapor phase induced phase inversion (that is, air casting) generally includes a coagulant (for example, water vapor) for inducing a phase inversion.
• the coagulant can be introduced to a polymeric material of a dope formulation as a vapor.
• a high concentration of vapor may condense and reduce the thermodynamic stability of the polymeric material dissolved in a solvent.
• polymer rich and polymer poor regions are formed from the vapor induced phase inversion resulting in the formation of a microstructure.
• Examples of coagulants for vapor induced phase separation include water, alcohols, amides and combinations thereof.
• multiple layers of dope and coagulant formulations may be cast as a sheet to form a three layer sheet 100 as illustrated in FIG. 4.
• FIG. 4 illustrates a three layer sheet 100 having a dope formulation layer 30, and a first 40 and second 50 coagulant formulation layers.
• the coagulant of the first and second coagulant formulations may be a liquid.
• the thickness of the dope and coagulant layers may be dependent on the viscosity and flow of the dope and coagulant formulations, and the configuration of a multilayer extrusion die.
• An interface 70 may be formed where the dope formulation layer 30 is cast on to a first coagulant formulation 40 layer.
• a first surface 60 of the three layer sheet 100 may be formed where the dope formulation layer 30 is cast on to a second coagulant formulation 50 layer.
• the first coagulant formulation 40 and dope formulation 30 layers at the interface 70 provide for flow and diffusion of a portion of the first coagulant formulation 40 layer into the dope formulation layer 30 effecting a first phase inversion.
• the second coagulant formulation 50 and dope formulation 30 at the first surface 60 provide for flow and diffusion of a portion of the second coagulant formulation 50 layer into the dope formulation layer 30 effecting a second phase inversion.
• Phase inversions at first and second surfaces of a dope formulation layer can occur when first and second coagulant formulation layers are each located on opposite surfaces of the dope formulation layer.
• the resulting phase inversions at the first and second surfaces form first and second microstructures.
• the morphology and depth of microstructures may be different or the same in membranes having more than one microstructure.
• the selection of membrane microstructures may be further selected by the concentration and selection of the components of the dope and coagulant formulations, and processing conditions.
• dope and coagulant formulations may be simultaneously cast at room temperature.
• dope and coagulation formulations may be simultaneously cast by means of a multilayer extrusion die 200 of FIG. 1.
• the multilayer extrusion die 200 may cast the dope and coagulant formulations as layers to form a sheet, where the layers are substantially linear in a cross-web or an x-dimension.
• a phase inversion process may be initiated by diffusion of a portion of a coagulant formulation layer into a dope formulation layer after the coagulant and dope formulations have exited the extrusion head 220 as illustrated in FIG. 1 and FIG. 2.
• the process can include metering the dope and coagulant formulations having a selected viscosity using a multilayer extrusion die 200 of FIG. 1 to form a multilayer sheet, where the dope and coagulant formulation layers partially or fully coagulate to form a microporous membrane.
• Pore sizes may be measured by the Bubble Point Pressure method described in the Examples section. Some other pore size and pore size distribution measurement methods may include solute retention, and flow/pressure techniques. Solvent phase inversion techniques are disclosed in Keating, "Synthetic Polymeric Membranes, A Structural Perspective", 2 nd Ed., John Wiley and Sons, 1995. A phase inversion of this disclosure may include diffusion of dope and coagulant formulation layers through a liquid-liquid polymer surface. A portion of a coagulant formulation layer diffuses into a dope formulation layer. The coagulant of the coagulant formulation may be thermodynamically compatible with the solvent of the dope formulation and/or other additives in order facilitate movement and diffusion of the coagulant within the dope formulation layer.
• the coagulant may generally be incompatible with the polymeric material of the dope layer reducing the solvency or compatibility of the polymeric material in the solvent.
• the instability creates a phase inversion of the polymeric material resulting in the formation of a microstructure.
• the microstructures of the membranes can have pores which are asymmetric or symmetric through the thickness or z-dimension of the membrane.
• a number of microstructures may be formed which may be dependent on the dope and coagulation formulations used and the processing parameters.
• a first microstructure may be the same or different than a second microstructure. The first and second microstructures may provide a continuous or discontinuous path through the membrane.
• the formation of the microstructures may depend on the concentration of some of the components (for example, polymeric material, coagulant, coating adjuvant) of the dope and coagulant formulations.
• the morphology of the microstructure may further depend on the metering (for example, layer thickness) of the dope and coagulant formulations and/or the rate of phase inversion.
• the microstructure morphology may also depend on the phase inversion mechanism, and related pressure and temperature processing conditions.
• the pores of a microstructure may be open and/or closed cells.
• a first face of the membrane may have relatively small diameter pores, while the second or opposite face may have relatively large diameter pores.
• the ratio of pores sizes at the first face to pore sizes at the second face of the membrane may in a range of 10 : 1 to 100:1.
• FIG. 5 of Example 1 is a SEM micrograph illustrating the generally symmetrical porous structure.
• the pores may have an average diameter of 0.05 to 25 microns.
• the pore diameter is in a range of 0.5 to 10 microns.
• the pores of a microstructure have a generally symmetrical morphology.
• FIG. 6 of Example 2 is an SEM micrograph illustrating a membrane having first and second microstructures.
• the membrane has a porous structure comprising first and second faces extending in an x-dimension.
• a first face has a first microstructure having parallel elongated cylindrical pores extending in a z-dimension formed from a multilayer liquid induced phase separation.
• the second face has a second microstructure having ellipsoidal pores formed from a vapor induced phase separation.
• FIG. 7 of Example 2 illustrates a surface scan (planar view) of the first face of the membrane.
• the dope formulation may have different coagulation formulations on different faces of the dope formulation effecting phase inversions, which may result in the formation of similar or different microstructures on the faces.
• an article has a porous structure comprising first and second faces extending in an x-dimension.
• the first face has a first microstructure
• the second face has a second microstructure.
• the first and second faces are interconnected by the first and second microstructures.
• FIG. 8 of Example 3 is a SEM micrograph illustrating a membrane having first and second microstructures.
• the dope formulation layer of Example 3 contained a porogen, and the first coagulant formulation layer comprised a coating adjuvant.
• the depth of a first microstructure in a z-dimension formed by a multilayer liquid induced phase separation is in a range of 5 to 95 percent of a membrane thickness.
• the depth of a second microstructure in a z-dimension formed by a vapor induced phase separation is in a range of 5 to 95 percent of the membrane thickness.
• Thickness of the membranes may be dependent on the thickness of the dope and coagulant formulation layers when cast, and the subsequent removal of solvents followed by drying. Thicknesses of the membrane may be in the range of 20 to 200 microns, and more preferably in a range of 40 to 150 microns. Most preferably, the membrane thickness is in a range of 50 to 100 microns.
• a microporous membrane may be formed by simultaneously casting a dope formulation in between first and second coagulant formulations.
• the depth of a first microstructure formed by a multilayer induced phase separation is in a range of 5 to 95 percent of a membrane thickness.
• the depth of a second microstructure formed by a multilayer induced phase separation is in a range of 5 to 95 percent of a membrane thickness.
• a microporous membrane having first and second microstructures formed by multilayer induced phase separation has different first and second microstructures.
• At least two dope formulations and at least two coagulant formulations being simultaneously cast and further optionally comprising a vapor coagulant to form a multizone microporous membrane. It will be appreciated for one to be able to form a multizone microporous membrane having multiple dope and coagulant layers comprising multiple zones or microstructures.
• BPP Bubble Point Pressure
• WFR Water Flow Rate
• Example 1 Dope and coagulant formulations were fed to a multilayer extrusion die of FIG. 1
• a multilayer sheet was coextruded from a multilayer extrusion die and transferred to a backup roll around which corona-treated polyester film backing (20 to 50 microns in thickness) was conveyed. The backing was advanced at a line speed of 150 cm/minute.
• PEI polyetherimide
• NMP l-methyl-2-pyrrolidinone
• the viscosity of the coagulant formulation was 70 centipoise.
• the dope and coagulant formulations were cast as layers on to one another through the multilayer extrusion die forming an interface, and the two-layer coating was commenced with a gap of approximately 500 microns between the multilayer extrusion die and the backup roll.
• the results of the multilayer induced phase inversion are illustrated in the cross- sectional SEM shown in FIG. 5.
• the resulting microporous membrane can be characterized by a mixture of closed cells and pore size diameters of about 1 to 2 microns.
• the morphology of the membrane is generally symmetric extending from one face of the membrane to another.
• Example 2 Dope formulation and first coagulant formulations were fed to a multilayer extrusion die of FIG. 1 (U.S. Patent Publication No. 2007/0128425) by syringe pumps (Model PHD 2000; Harvard Apparatus; Holliston, MA) which was used to meter the dope formulation and the first coagulant formulations to the cavities of the multilayer extrusion die at volumetric flow rates ranging from 5 to 40 ml/minute.
• a multilayer sheet was extruded from the multilayer extrusion die and transferred to a backup roll around which corona-treated polyester film backing (20 to 50 microns in thickness) was conveyed. The backing was advanced at a line speed of 150 cm / minute.
• the viscosity of the coagulant formulation was 54 centipoise.
• the dope and first coagulant formulations were cast as layers on to one another through the multilayer extrusion die forming an interface. A first surface of the dope formulation layer was opposite the interface formed from the dope formulation and coagulant formulation layers.
• the two-layer coating was commenced with a gap of approximately 500 microns between the multilayer extrusion die and the backup roll.
• a second coagulant having a coagulant as a vapor was introduced at the first surface of a multilayer membrane having a first microstructure resulting in a vapor induced phase separation.
• Dope formulation and first coagulant formulation layers were cast as described above undergoing a liquid-polymer induced phase separation followed by subsequent exposure of the first surface of the membrane to water vapor created by the injection of steam within an 8 meter long drying oven. Through steam injection, a relative humidity of between about 50 and 60% was maintained. Oven parameters used are listed in Table 1.
• T/B Top/Bottom (airflow configuration of air flotation nozzles or air bars - TEC (Grace TEC Systems;
• the results from the multizone microporous membrane are illustrated in the cross- sectional SEM shown in FIG. 6 and planar view of FIG. 7.
• the resulting microporous membrane is characterized by a mixture of closed cells and pore sizes of about 1 to 2 microns in diameter.
• the first zone of the liquid induced phase inversion has a morphology representative of porous elongated voids having a thickness of about 32 microns (about 50 percent of the thickness of the membrane in a z-dimension).
• the second zone of the vapor induced phase inversion has a spongy microstructure having a thickness of about 35 microns (about 50 percent of the thickness of the membrane in a z- dimension).
• the pores of the first and second zones appear to be interconnected across the zones with different pore structures.
• the membrane had filtration properties (BPP) of about 20.8 psi. WFR testing resulted in no flow without surface treatment, and the WFR was minutes with both sides etched.
• a dope formulation and a first coagulant formulation were fed to a multilayer extrusion die using a similar equipment arrangement to Example 2.
• the viscosity of the dope formulation was 3,400 centipoise.
• the flow rate of the dope formulation was 20 ml/minute.
• One of the adjacent slots of the multilayer extrusion die was fed a coagulant formulation at a flow rate of 10 ml/minute.
• the two-layer coating was commenced with a gap of approximately 500 microns between the multilayer extrusion die and the backup roll.
• a second coagulant was used in a similar manner as Example 2.
• the results from the formation of a multizone microporous membrane are illustrated in FIG. 8.
• the resulting microporous membrane had an open cellular morphology having a pore size distribution of about 0.6-1 microns.
• the first zone of the liquid induced phase inversion had porous elongated voids and a thickness of about 75 microns, and a second porous zone resulting from the vapor induced phase separation having a spongy microstructure had a thickness of about 25 microns.
• the WFR was 2 minutes with no surface treatment, and the WFR was 18 seconds after etching both sides of the membrane.

Landscapes

• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dispersion Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Manufacturing & Machinery (AREA)
• Separation Using Semi-Permeable Membranes (AREA)
• Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
• Medicinal Preparation (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39788886

Family Applications (1)

Country Status (8)

Families Citing this family (25)

Citations (14)

Family Cites Families (45)

• 2007
  • 2007-03-28 US US11/692,257 patent/US7842214B2/en not_active Expired - Fee Related
• 2008
  • 2008-02-22 EP EP08730443.2A patent/EP2134455B1/en not_active Not-in-force
  • 2008-02-22 JP JP2010501034A patent/JP5432118B2/ja not_active Expired - Fee Related
  • 2008-02-22 BR BRPI0809206-0A patent/BRPI0809206A2/pt not_active Application Discontinuation
  • 2008-02-22 KR KR1020097020823A patent/KR101461693B1/ko not_active Expired - Fee Related
  • 2008-02-22 SG SG201102812-3A patent/SG171587A1/en unknown
  • 2008-02-22 CN CN200880010112.8A patent/CN101646483B/zh not_active Expired - Fee Related
  • 2008-02-22 WO PCT/US2008/054638 patent/WO2008118580A1/en not_active Ceased

Patent Citations (16)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events